ASH 2022 | The importance of integrating genomic and cytogenetic data in treatment decisions for AML
Nigel Russell
• 12 Dec 2022
Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, emphasizes the importance of using genomic and cytogenetic data to stratify patients with acute myeloid leukemia (AML) into different risk groups and select the most effective therapy based on their risk, commenting on data from the AML19 trial (ISRCTN78449203). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: Honoraria, Research Funding, Speakers Bureau; Astellas: Honoraria; Jazz Pharma: Research Funding; Servier: Honoraria.
